Skip to main content

Catalyst Calendar

Tue, Sep 8, 2026

1 updates

8:17 AM

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

verupharma.com

Wed, Sep 2, 2026

1 updates

8:30 AM

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

verupharma.com

Mon, Aug 10, 2026

1 updates

6:30 AM

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Enrollment • Phase 2Enrollment milestone Mon, Aug 10, 2026, 6:30 AM EDTverupharma.com

Tue, Aug 4, 2026

1 updates

8:30 AM

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

verupharma.com

Mon, Aug 3, 2026

1 updates

8:30 AM

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

verupharma.com

Thu, Jul 30, 2026

1 updates

8:30 AM

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

verupharma.com

Mon, Jul 27, 2026

1 updates

8:10 AM

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Enrollment • Phase 2oral presentation Mon, Jul 27, 2026verupharma.com